Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on December 21, 2023. The document announced the availability of a final guidance for industry entitled "Development of Monoclonal Antibody Products Targeting SARS- CoV-2 for Emergency Use Authorization." The document was published with an incorrect docket number. This document corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 21 (Wednesday, January 31, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 21 (Wednesday, January 31, 2024)]
[Notices]
[Page 6119]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-01836]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-D-0361]
Development of Monoclonal Antibody Products Targeting SARS-CoV-2
for Emergency Use Authorization; Guidance for Industry; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register on December 21, 2023. The
document announced the availability of a final guidance for industry
entitled ``Development of Monoclonal Antibody Products Targeting SARS-
CoV-2 for Emergency Use Authorization.'' The document was published
with an incorrect docket number. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Maria Clary, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 4638, Silver Spring, MD 20993-0002, 240-
402-8615.
SUPPLEMENTARY INFORMATION: In the Federal Register of December 21, 2023
(88 FR 88401), in FR Doc. 2023-28092, the following correction is made:
1. On page 88401, in the first column in the header of the
document, and in the ADDRESSES section, in the second and third lines
of the first paragraph, the Docket No. is corrected to read ``Docket
No. FDA-2024-D-0361.''
Dated: January 25, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-01836 Filed 1-30-24; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.